Bacteriophage-based therapies are emerging as a promising alternative to antibiotics in combating antibiotic resistance. This review explores the potential of bacteriophages (BPs) in treating infections caused by antibiotic-resistant pathogens, highlighting their specificity, effectiveness when combined with antibiotics, and various formulation strategies. BPs are natural viral predators that target specific bacteria, reducing the risk of disrupting beneficial microflora. They can be delivered through various methods, including polymeric encapsulation, liposome encapsulation, and microneedle platforms, enhancing their stability and efficacy. BPs also exhibit synergistic effects with antibiotics, enhancing their ability to kill resistant bacteria. Preclinical and clinical studies demonstrate the potential of BP-based therapies in treating respiratory, gastrointestinal, and systemic infections. However, challenges such as bacterial resistance to BPs and the need for tailored treatment regimens remain. The review emphasizes the importance of phage sensitivity profiles and the development of effective delivery systems to maximize the therapeutic potential of BPs. Overall, bacteriophage-based therapies offer a personalized and potent solution against antibiotic resistance, with significant potential in reshaping the future of infectious disease management.Bacteriophage-based therapies are emerging as a promising alternative to antibiotics in combating antibiotic resistance. This review explores the potential of bacteriophages (BPs) in treating infections caused by antibiotic-resistant pathogens, highlighting their specificity, effectiveness when combined with antibiotics, and various formulation strategies. BPs are natural viral predators that target specific bacteria, reducing the risk of disrupting beneficial microflora. They can be delivered through various methods, including polymeric encapsulation, liposome encapsulation, and microneedle platforms, enhancing their stability and efficacy. BPs also exhibit synergistic effects with antibiotics, enhancing their ability to kill resistant bacteria. Preclinical and clinical studies demonstrate the potential of BP-based therapies in treating respiratory, gastrointestinal, and systemic infections. However, challenges such as bacterial resistance to BPs and the need for tailored treatment regimens remain. The review emphasizes the importance of phage sensitivity profiles and the development of effective delivery systems to maximize the therapeutic potential of BPs. Overall, bacteriophage-based therapies offer a personalized and potent solution against antibiotic resistance, with significant potential in reshaping the future of infectious disease management.